Trial reportDiabetes, obesity & metabolism2009
Biomarkers of body iron stores and risk of developing type 2 diabetes.
Trial report in Diabetes, obesity & metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Iron metabolism and type 2 diabetes mellitus: A meta-analysis and systematic review.Journal of diabetes investigation · 2020Pooled it
- Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis.BMC medicine · 2012Pooled it
- Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis.PloS one · 2012Pooled it
- Iron status determined changes in health measures induced by nordic walking with time-restricted eating in older adults- a randomised trial.BMC geriatrics · 2024Trial
- A lipidomics analysis of the relationship between dietary fatty acid composition and insulin sensitivity in young adults.Diabetes · 2013Trial
- Association between serum ferritin and osteocalcin as a potential mechanism explaining the iron-induced insulin resistance.PloS one · 2013Trial
- Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program.Obesity (Silver Spring, Md.) · 2010Trial
- Metals in the human liver: An underappreciated risk factor of hepatic insulin resistance and associated pathophysiology.Environmental pollution (Barking, Essex : 1987) · 2025Review
- Threshold-effect of ferritin levels with pathoglycemia in Chinese adults: a cross-sectional study based on China health and nutrition survey data.BMC endocrine disorders · 2025Article
- Article
- Article
- Mitochondrial Iron Metabolism: The Crucial Actors in Diseases.Molecules (Basel, Switzerland) · 2022Review
- Article
- Soluble transferrin receptor can predict all-cause mortality regardless of anaemia and iron storage status.Scientific reports · 2022Article
- Relationship between soluble transferrin receptor and type 2 diabetes mellitus: A meta-analysis.Journal of diabetes investigation · 2021Article
- Response to "Relationship between soluble transferrin receptor and type 2 diabetes mellitus: A meta-analysis".Journal of diabetes investigation · 2021Article
- Association between Iron Status and Incident Type 2 Diabetes: A Population-Based Cohort Study.Nutrients · 2020Article
- Dietary Nonheme, Heme, and Total Iron Intake and the Risk of Diabetes in Adults: Results From the China Health and Nutrition Survey.Diabetes care · 2020Article
- Hepcidin, soluble transferrin receptor and IL-6 levels in obese children and adolescents with and without type 2 diabetes mellitus/impaired glucose tolerance and their association with obstructive sleep apnea.Journal of endocrinological investigation · 2018Article
- Trace element status in type 2 diabetes: A meta-analysis.Journal of clinical and diagnostic research : JCDR · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
aimIron may contribute to the pathogenesis of type 2 diabetes mellitus (DM) by inducing oxidative stress and interfering with insulin secretion. Elevated ferritin levels are associated with increased DM risk among healthy individuals. However, it is yet unknown if ferritin predicts DM incidence among high-risk individuals with impaired glucose tolerance (IGT). Furthermore, the association between soluble transferrin receptors (sTfR), a novel marker of iron status, and DM risk has not yet been prospectively investigated in these individuals. We conducted this study to evaluate the association between baseline levels of ferritin and sTfR and the risk of developing DM among overweight and obese individuals at high risk of DM.
methodsThis nested case-control study (280 cases and 280 matched controls) was conducted within the placebo arm of the Diabetes Prevention Program, is a clinical trial conducted among overweight/obese individuals with IGT. Ferritin and sTfR levels were measured by immunoturbidimetric assays. Incident DM was ascertained by annual 75-g oral glucose tolerance test and semi-annual fasting glucose.
resultsCompared with controls, cases had higher sTfR levels (3.50 +/- 0.07 vs. 3.30 +/- 0.06 mg/l; p = 0.03), but ferritin levels were not statistically different. The multivariable odds ratios (OR) and 95% confidence intervals (95% CI) for DM incidence comparing highest with the lowest quartiles of sTfR was 2.26 (1.37-4.01) (p-trend: 0.008).
conclusionsModestly elevated sTfR levels are associated with increased DM risk among overweight and obese individuals with IGT. Future studies should evaluate factors determining sTfR levels and examine if interventions that lower body iron stores reduce DM incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.